ENDRA Life Sciences withdraws planned S-1 offering
ENDRA Life Sciences Inc. requested voluntary withdrawal of its Registration Statement on Form S-1 (File No. 333-288575), effective May 26, 2026 or the earliest practicable date.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
ENDRA Life Sciences Inc. requested voluntary withdrawal of its Registration Statement on Form S-1 (File No. 333-288575), effective May 26, 2026 or the earliest practicable date. The company states the registration was not declared effective and no securities covered by the Registration Statement have been issued or sold. The company also requested that fees paid under Rule 457(p) be credited to its account for future use.
Insights
Voluntary S-1 withdrawal and fee credit request; routine corporate action.
The filing requests withdrawal of a Form S-1 (File No. 333-288575) filed July 9, 2025 and amended July 16 and July 25, 2025, stating the registration was not declared effective and no securities were issued. The registrant asks the Commission to credit fees under Rule 457(p).
Practical dependencies include the SEC's procedural consent and fee-credit posting. Subsequent filings or disclosures would show if the company later pursues a new offering.
Key Figures
Key Terms
Registration Statement on Form S-1 regulatory
Rule 457(p) regulatory
not declared effective regulatory
Offering Details
AI-generated analysis. How Rhea-AI works. Not financial advice.